First nationwide Prostate Cancer registry for identifying effective treatment options

NewsGuard 100/100 Score

RemedyMD (www.RemedyMD.com), the leading provider of Patient registry software, today announced the first nationwide Prostate Cancer registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: www.remedymd.com/cer100/prostate.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s prostate cancer registry tracks the survival, recurrence, side effects, longitudinal quality of life, and cost of various management strategies for localized prostate cancer including:

  • Active surveillance
  • Radical prostatectomy (conventional, robotic, and laparoscopic)
  • Radiotherapy (conformal, brachytherapy, proton-beam, and intensity-modulated radiotherapy)

The prostate cancer registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies,” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new prostate cancer registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to prostate cancer research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of prostate cancer researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/prostate.html

RemedyMD Resources:

Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html

Ways to leverage prostate cancer registry: www.remedymd.com/CER100/prostate.html

Comparative Effectiveness Research: www.remedymd.com/cer_home.html

Disease Registry Software: www.remedymd.com/registries_home.html

Institute of Medicine’s Top 100 Priorities for CER: www.remedymd.com/cer_kit.html

www.RemedyMD.com.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases